June 5 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:
NRX PHARMACEUTICALS, INC. $(NRXP)$ FILES ABBREVIATED NEW DRUG APPLICATION (ANDA) FOR PRESERVATIVE-FREE IV KETAMINE
NRX PHARMACEUTICALS INC - ANTICIPATES PRIORITY REVIEW DUE TO KETAMINE SHORTAGE
NRX PHARMACEUTICALS INC - NDA SUBMISSION FOR NRX-100 IN SUICIDAL DEPRESSION, PDUFA EXPECTED LATE 2025
Source text: ID:nPn1NKFmFa
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.